Moneycontrol
HomeNewsEye on indiaVideos3-Point Analysis | Multiplex stocks hit by coronavirus outbreak, investors need to remain cautious

3-Point Analysis | Multiplex stocks hit by coronavirus outbreak, investors need to remain cautious

Moneycontrol's Sakshi Batra does a 3-Point Analysis to understand what's the road ahead for them.

March 11, 2020 / 20:03 IST
Story continues below Advertisement

Stocks of listed multiplex operators PVR and INOX Leisure fell sharply last week on news of rising confirmed COVID-19 cases in the country. With the increase in the number of cases, footfalls in multiplexes are expected to decline as people tend to avoid public spaces.

Despite the slowdown in the media industry, one segment that has stood out is that of multiplexes, the third-largest segment in the Indian media and entertainment sector by revenue, after television and print.

Story continues below Advertisement

Despite challenging economic environment, the sector managed to deliver stable advertising growth in 9M FY20. Multiplexes will be worst affected if COVID- 19 spreads widely. Investors should pay close attention to multiplex stocks keeping it in their watch list.

Moneycontrol's Sakshi Batra does a 3-Point Analysis to understand what's the road ahead for them.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show
Moneycontrol News
first published: Mar 11, 2020 07:23 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!